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Abstract
Restless legs syndrome (RLS) and Parkinson’s disease (PD) are both common neurological disorders. There has been
much debate over whether an etiological link between these two diseases exists and whether they share a
common pathophysiology. Evidence pointing towards a link includes response to dopaminergic agents in PD and
RLS, suggestive of underlying dopamine dysfunction in both conditions. The extrastriatal dopaminergic system, in
particular altered spinal dopaminergic modulation, may be variably involved in PD patients with RLS symptoms. In
addition, there is now evidence that the nigrostriatal system, primarily involved in PD, is also affected in RLS.
Furthermore, an association of RLS with the parkin mutation has been suggested. The prevalence of RLS has also
been reported to be increased in other disorders of dopamine regulation. However, clinical association studies and
functional imaging have produced mixed findings. Conflicting accounts of emergence of RLS and improvement in
RLS symptoms after deep brain stimulation (DBS) also contribute to the uncertainty surrounding the issue. Among
the strongest arguments against a common pathophysiology is the role of iron in RLS and PD. While elevated iron
levels in the substantia nigra contribute to oxidative stress in PD, RLS is a disorder of relative iron deficiency, with
symptoms responding to replacement therapy. Recent ultrasonography studies have suggested that, despite
overlapping clinical features, the mechanisms underlying idiopathic RLS and RLS associated with PD may differ. In
this review, we provide a concise summary of the clinical, imaging and genetic evidence exploring the link
between RLS and PD.
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Introduction
The common features of dopaminergic dysfunction and
response to dopaminergic agents in RLS and PD,
together with comorbidity in some patients has fuelled
the concept that these two diseases may share the same
pathophysiology [1]. We review the clinical, imaging and
genetic evidence, exploring the link between RLS (rest-
less legs syndrome) and PD (Parkinson’s disease).
PD and RLS: an overview
PD is a progressive neurodegenerative disorder charac-
terised by pathologic intraneuronal alpha-synuclein-posi-
tive Lewy bodies and neuronal cell loss. In particular,
involvement of dopaminergic cells in the substantia
nigra pars compacta is associated with development of
the motor features of the disease. The cardinal clinical
symptoms and signs of PD are bradykinesia, rigidity, tre-
mor, postural instability and freezing attacks [2]. The
prevalence of PD increases with age, affecting 1-2% of
the population over the age of 65 years, and 3% of those
over 85 years [3]. Several monogenic forms of PD and
numerous genetic susceptibility factors have been identi-
fied [4,5]. Sleep disturbances have been widely reported
in PD, although an increased incidence of periodic leg
movements of sleep (PLMS) is debatable, with polysom-
nography studies revealing mixed findings [6-10].
Restless legs syndrome (RLS) was initially described by
Ekbom [11] in 1945. It tends to present in mid to later
life and has a prevalence of 2.7-10% in Western popula-
tions [12,13]. It is reportedly much less common amongst
Asians [14]. Four essential diagnostic criteria were pro-
posed by the International Restless Legs Syndrome Study
Group (IRLSSG) in 1995; 1. An urge to move the legs
associated with paresthesias, 2. motor restlessness, 3.
worsening at rest with at least partial relief by activity,
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and 4. worsening at night [15,16]. In 2003, at a consensus
conference at National Institute of Health, USA, these
criteria were modified and new criteria developed for the
diagnosis of RLS in the cognitively impaired elderly and
in children [17]. Additional features supporting a diagno-
sis of RLS include sleep disturbance, periodic limb move-
ment in sleep (PLMS), chronic symptoms with
exacerbations and remissions, a positive family history
and improvement of symptoms with dopaminergic drugs.
RLS can be associated with medical conditions such as
renal failure, iron deficiency, neuropathy, and pregnancy
[18-22]. Family history, with an autosomal dominant
mode of inheritance may be present in more than half of
the cases. Five genetic loci for RLS have been reported in
different pedigrees, of which 4 are autosomal dominant
and one autosomal recessive [23]. The detection of PLMS
during overnight polysomnography is the the most fre-
quent objective abnormality and can be demonstrated in
the majority of RLS patients [24-27]. However, the absence
of PLMS does not exclude RLS [26].
Evidence of dopaminergic dysfunction in RLS
Observation studies of RLS in diseases which involve
dopaminergic systems lend support to the hypothesis
that dopaminergic dysfunction is present in RLS. One
family with comorbidity of Huntington’s disease (HD)
and idiopathic RLS has been reported. All family mem-
bers affected by RLS also had HD, but not vice versa [28].
Ondo and colleagues found a very high rate (33%) of
undiagnosed RLS in their patients presenting with essen-
tial tremor. However, unlike other “secondary” forms of
RLS, this finding was also associated with a high familial
history of RLS [29]. A study of comorbidities in Tourette
syndrome (TS) including RLS investigated 144 probands
with TS or chronic tics and their parents. RLS was pre-
sent in 10% of probands and 23% of parents with no gen-
der differences [30].
Dopaminergic dysfunction has also been implicated in
thyroid disorders. In a study of 146 patients with bio-
chemically confirmed hyper- or hypothyroidism and 434
controls, none of the patients satisfied all the IRLSSG cri-
teria of RLS [31]. However, 8.2% of patients had RLS-like
symptoms (satisfying the first 3 IRLSSG criteria) com-
pared to 0.9% of controls. Four (33.3%) of these patients
reported complete resolution of their symptoms after
their thyroid condition was treated. Interestingly, there
was also a report of RLS emerging after the initiation of
L-thyroxine treatment in a hypothyroid patient with low
serum ferritin [32]. Upon withdrawal of L-thyroxine,
there was a significant improvement in the RLS severity
score, PML index, number of arousals due to PLMS,
sleep efficiency, and biochemical parameters. Hence, RLS
symptoms can complicate thyroxine replacement in
hypothyroid patients with low serum ferritin.
Pathological evidence of dopamine dysfunction in PD and
RLS
Post-mortem studies in PD demonstrate loss of nigral
neurons resulting in striatal dopamine deficiency, with
differing morphological lesion patterns according to the
clinical subtypes of PD. Cell loss in the ventrolateral
part of the substantia nigra pars compacta (SNPC) pro-
jecting to the dorsal putamen is more prominent in the
akinetic-rigid type, whereas tremor-dominant PD shows
predominantly medial SNPC cell loss [33]. Variability in
lesion patterning might explain why some patients with
PD may develop RLS. In addition, loss of dopamine 2
(D2) receptors has been documented in advanced PD
[33].
At autopsy of 8 patients with primary RLS, there was a
significant decrease in dopamine 2 (D2) receptors in the
putamen compared to a neurologically normal control
group. The decrease in the D2 receptors correlated to the
severity of the RLS [34]. This evidence that the nigros-
triatal dopaminergic system is affected in both RLS and
PD might provide a stronger argument for an etiologic
link between the two. Moreover, there were significant
increases in tyrosine hydroxylase in the substantia nigra,
but not in the putamen of the RLS group. Phosphorylated
(active) tyrosine hydroxylase was found to be increased in
both the substantia nigra and putamen. These findings
are consistent with data from animal iron deficiency
models demonstrating increased presynaptic dopaminer-
gic activity [34].
Ondo et al [35] performed bilateral stereotactic 6-
hydroxydopamine (6-OHDA) lesions in dopaminergic
diencephalic spinal (A11) neurons in rats resulting in a
54% reduction in A11 tyrosine hydroxylase staining cells
compared to rats receiving sham treatment. Multiple
90- 120 minute video epochs demonstrated an increased
average number of standing episodes and increased total
standing time in four lesioned rats when compared with
two sham rats. Treatment of the lesioned rats with
intramuscular pramipexole subsequently resulted in
fewer standing episodes and less total standing time.
The results supported the authors’ suspicion that RLS
involves dopaminergic A11 cells.
Of note, post-mortem examinations in RLS patients
have not demonstrated dopaminergic cell loss in SNPC
[36], presence of Lewy bodies or positive alpha-synu-
clein immunohistochemistry staining [37].
Genetic studies
Parkin mutations were found in 10 of 20 patients in 2
families with idiopathic RLS [38]. The clinical phenotype
did not differ between RLS patients with and without a
parkin mutation [38]. A recent study of 11 patients with 2
parkin mutations and 11 sex-matched patients with idio-
pathic PD found the prevalence of RLS to be 45% and 0%
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respectively (p = 0.04), providing stronger evidence of an
association [39].
However, other genetic evidence has not yielded any
conclusive evidence of a link between RLS and PD.
There is a single report of a PD patient with a PINK1
mutation presenting with RLS symptoms [40]. A family
with hereditary PD, essential tremor and RLS was also
recently described. Of 65 family members examined, 11
had PD and 15 had RLS (of which 3 had both PD and
RLS) with an autosomal dominant inheritance pattern.
However, testing for known gene mutations in PD
-associated genes was negative [41]. A study investigat-
ing a possible genetic association of the COMT val158-
met polymorphism with RLS yielded negative results.
The COMT val158met polymorphism, which leads to
reduced COMT activity, is linked to higher dopamine
availability and can influence phenotypic manifestations
in PD [42].
Clinical association studies
A number of clinical studies examining the association
between RLS and PD have been conducted since the
introduction of IRLSSG criteria, with variable findings
[43-52]. In a study of 126 PD patients and 128 healthy
age-and sex-matched controls in India, RLS was found
to be present in 10 patients (7.9%) and 1 control (0.8%,
p = 0.01) [43]. PD patients with RLS were older and had
a higher prevalence of depression than those without
RLS.
Ondo et al [44] evaluated 303 PD patients and found
63 (20.8%) had symptoms of RLS. Neither PD patient
demographics nor PD treatments could reliably predict
the development of RLS symptoms. In 54 (68%) of 79
patients with PD/RLS, the PD symptoms preceded the
RLS symptoms. Compared with patients with idiopathic
RLS, patients with PD/RLS were older at RLS onset,
were less likely to have a family history of RLS, and had
lower serum ferritin levels.
A study in the Japanese population also found preva-
lence of RLS to be significantly higher in PD patients
than in control subjects (12% vs. 2.3%) [45]. However,
PD patients with RLS were younger than those without
RLS. A cohort of 113 PD patients from Austria, revealed
that the 24% with comorbid definite RLS were younger
(63.1+/-8.6 vs. 68.8 +/-9.0 years; p = 0.004), and received
lower levodopa equivalent doses [46].
A Brazilian study reported the prevalence of RLS to be
18.75% in 48 patients with PD. No significant differences
were observed regarding clinical variables or biochem-
ical parameters [47]. It has also been suggested that
long-term antiparkinson therapy rather than PD itself
contributes to the development of RLS. A Korean study
found prevalence of RLS among 447 PD patients to be
16.3%, with multivariate logistic regression analysis
revealing duration of antiparkinson treatment to be the
most significant factor contributing to the development
of RLS in this group [48].
A few studies have commented of findings not sup-
portive of co-morbid occurrence of PD and RLS. A case
control survey of the prevalence of definite RLS in 118
PD patients did not demonstrate a significantly increase
prevalence of either primary RLS alone or combined
with secondary RLS as compared to gender and age
matched controls [49].
Of 269 Caucasian PD patients studied in the Nether-
lands, 11% had definite RLS, similar to the prevalence of
RLS in the general population. PD-RLS patients were
more likely to be female (69% vs. 32%, p < 0.001),
although this was the only significant difference between
the 2 groups. Severity of RLS symptoms correlated posi-
tively with PD severity. Both studies acknowledged that
the prevalence of RLS may have been underestimated
due to dopaminergic treatment [50].
Tan et al [51] studied 125 PD patients in Singapore
and found that 19 (15.2%) patients had motor restless-
ness. Of these, one (0.8%) patient had RLS-like symp-
toms closely correlated to wearing “off” effect of
levodopa. However, none of the patients satisfied the
IRLSSG diagnostic criteria of RLS. This was not signifi-
cantly different compared to the 0.6% and 0.1% RLS
prevalence in the general population and clinic
population.
A subsequent case-control study of 400 study subjects
in Singapore demonstrated only a weak association
between RLS and PD, with prevalence of RLS in PD
patients and controls 3.0% and 0.5% respectively (p =
0.07) [52].
Functional imaging studies
Functional imaging studies have demonstrated that there
is decreased [18 F]-dopa uptake and [123I]-ß-CIT bind-
ing in PD. However, the findings in RLS have been
inconclusive, with some studies showing mild reduction
in postsynaptic dopaminergic status [53,54], and
another, normal D2 receptor binding compared to con-
trols [55]. Two [18 F]-dopa PET studies demonstrated a
slight decrease in striatal [18 F]-dopa uptake in RLS
patients compared to healthy controls [54,56], suggest-
ing presynaptic dopaminergic dysfunction in the stria-
tum. However, a third study showed normal values for
presynaptic dopaminergic function [57].
Sonographic studies
Sonography of 41 patients with idiopathic RLS, 19 with
RLS-PD, 25 with idiopathic PD and 35 controls revealed
a significant decrease in substantia nigra (SN) region
echogenicity in the idiopathic RLS group compared with
other groups (p < 0.0001). In contrast, the PD-RLS
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group had increased echogenicity of the SN area com-
pared with the control group (p < 0.05) and idiopathic
RLS group (p < 0.0001), suggesting different pathological
processes underlying idiopathic and PD associated RLS
[58]. Another sonographic study of 63 PD patients of
which 26 had comorbid RLS, 40 patients with idiopathic
RLS and 40 controls demonstrated similar findings [59].
What impact does DBS surgery for PD have on RLS?
The emergence of RLS after subthalamic nucleus (STN)
deep brain stimulation (DBS) in patients with PD has
been reported [60]. Eleven of 195 patients with STN
DBS reported new problematic symptoms of RLS after
surgery. The mean reduction in antiparkinsonian medi-
cation was 74%. The authors suggested that reduction of
anti-parkinsonian medication during STN DBS may
unmask symptoms of RLS. However, a recent prospec-
tive study of 17 patients undergoing STN DBS identified
6 patients with RLS with a mean IRLSSG rating score of
23 preoperatively. Postoperative scores at 4 weeks and 6
months were significantly improved at 14.8 (p = 0.027)
and 13.8 (p = 0.037) respectively. None of the patients
developed RLS postoperatively [61].
Problems with the common pathophysiology theory
Symptoms of RLS in PD are milder than in patients
with idiopathic disease [44] and may be difficult to dif-
ferentiate from other sensory and motor symptoms in
PD, in particular akathisia affecting the lower extremi-
ties [62,63]. RLS symptoms may also be a manifestation
of wearing-"off” phenomenon, a levodopa related com-
plication of PD [51,64].
Prolonged dopaminergic therapy in RLS patients, in
particular with levodopa use, may result in a phenom-
enon known as augmentation in which the severity of
symptoms increases, onset of symptoms begin earlier in
the day and more rapidly, and spread of distribution to
other body parts occurs. In contrast, PD patients
develop dyskinesias and motor fluctuations after treat-
ment with dopaminergic agents. These complications
are not seen in RLS patients.
Total iron and ferritin levels in the substantia nigra
region are increased in PD, causing oxidative stress and
possibly leading to dopaminergic degeneration [65]. On
the other hand, RLS is a disease of iron deficiency
[66-69]. CSF ferritin levels are low and CSF transferrin
levels are high in RLS patients compared to controls
[70]. RLS severity negatively correlates with serum ferri-
tin levels [69], even when the latter are within the nor-
mal range, and symptoms improve with replacement of
iron [21]. Utilizing MRI techniques, one study examined
regional brain iron concentrations in RLS and controls
[71]. Iron was significantly decreased in the substantia
nigra, and somewhat less significantly in the putamen,
both in proportion to RLS severity suggesting that brain
iron insufficiency may occur in some RLS patients. In a
transcranial ultrasound study, RLS patients had signifi-
cantly reduced midbrain areas of hyper-echogenicity
compared with control subjects, and even more mark-
edly reduced hyper-echogenicity compared with PD
[72]. A neuropathological study demonstrated increased
transferrin with decreased transferrin receptor expres-
sion in neuromelanin cells from the substantia nigra of
four RLS brains compared to four control brains. The
findings were consistent with iron deficiency except that
transferrin receptor expression was decreased rather
than increased. Decreased iron regulatory protein 1,
involved in the post-transcriptional regulatory mechan-
ism for transferrin receptor expression, was found in the
RLS brains. The authors postulated that RLS may result
from decreased iron regulatory protein 1 in neuromela-
nin cells resulting in destabilization of the transferrin
receptor mRNA and therefore cellular iron deficiency
[73].
Hypofunction of the endogenous opioid system has
been postulated to be a mechanism related to the patho-
genesis of RLS. Exposure to the iron chelator desferoxa-
mine in cell cultures of rat substantia nigra resulted in
DNA fragmentation while pre- administration of enke-
phalin (a delta opioid peptide) significantly protected
the cells from damage by iron deficiency [74].
Future prospects: questions to be answered
The link between PD and RLS has yet to be clearly
determined with clinical association studies differing
widely in their findings, with some finding the incidence
of RLS to be much greater in PD patients, and others
finding no difference from that in the general popula-
tion. These discrepancies could be addressed with pro-
spective long-term clinical studies of PD patients who
develop RLS and vice versa, with documentation of
exposure to dopaminergic therapies.
With the exception of the parkin mutation, genetic
studies have been failed to reveal any associations. We
propose that population based genetic association stu-
dies of PD plus RLS and linkage studies of PD plus RLS
as well as comparative studies of PD vs. PD-RLS vs. RLS
should be conducted.
Sonographic studies reveal notable differences between
PD and PD-RLS patients. Functional MRI studies have
yet to focus on those patients with PD-RLS. Prospective
functional imaging studies of PD vs. PD-RLS are needed
to better understand the mechanisms involved in these
disorders. To our knowledge, there have been no patho-
logical studies looking at patients with PD-RLS. Estab-
lishing the pattern of decreased D2 receptor density in
PD vs. PD and RLS vs. RLS may be valuable in under-
standing common pathophysiology. The reports
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purporting to DBS and RLS are conflicting, and more
studies need to be done to clarify the effect, with atten-
tion to adjustments in dopaminergic medications.
Conclusions
Certain similarities and differences exist between RLS
and PD. Dopaminergic disturbance appears to underpin
both diseases suggesting that there may be some overlap
in pathophysiology. However, there is sonographic evi-
dence that the actual mechanisms may not be identical.
A recent study suggests that the nigrostriatal dopami-
nergic system, primarily involved in PD, is also affected
in RLS. The literature appears to support a link between
the parkin mutation and RLS, although other genetic
studies have yielded mostly negative results. While some
advances have been made in understanding the link
between RLS and PD, much is yet to be elucidated par-
ticularly with regard to pathologic mechanisms and the
role of genetics. Prospective long-term clinical studies
are indicated to evaluate the exact relationship between
PD and RLS.
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